Q&A: Pfizer On Unlocking The Promise Of Real World Evidence
Real world evidence offers big potential to get medicines to the market, but exploiting the data is not always easy for companies. Pfizer's James Harnett explains the firm's RWE strategy and some of the challenges, like unstructured data and the need for incentives and standards for gathering the data.
You may also be interested in...
Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.
The norms on securing market access are being rewritten for cell and gene therapies.
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.